Company ProfilePremium

Trillium Ag

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
Trillium Ag - Company showcase

Year Founded & Workforce

2016

3 Employees

Trillium Ag logo

Trillium Ag Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Trillium Ag Overview

Trillium Ag is a Washington State agricultural biotechnology platform company founded in 2016. It is trying to solve the problem that has kept RNA interference from becoming a mainstream crop-protection category: naked double-stranded RNA breaks down quickly, crosses membranes poorly, and most economically important insect pests do not respond to it when they ingest it.

The company's Agrisome platform takes a different approach to each of these problems. It uses a single-stranded, structurally engineered RNAi trigger. It packages that trigger in programmable protein nanoparticles, which can also be loaded into engineered exosomes and stabilised in natural crystals for field use. AI-assisted sequence and particle design tools sit on top.

Trillium does not intend to become a vertically integrated pesticide maker. Its plan is to be an enabling-technology licensor and co-development partner to established crop-protection companies. A second business, the nPlanta plant-based cell-free protein expression kit, gives it an early source of product revenue and a research tool that also has customers in pharma and biotech.


What the company does

Trillium Ag develops biological crop-protection technology based on RNA interference. RNAi is a natural cellular process in which a short RNA sequence matching a target gene leads to that gene's messenger RNA being destroyed, which silences the gene. Silencing a gene essential to a pest's survival can kill the pest, or stop it feeding or reproducing. Because the sequence can match genes found only in the target species, the method is potentially far more selective than broad-spectrum synthetic chemistry.

The company's website states its long-term ambition plainly: crop protection that defends yields without damaging the surrounding ecosystem. It says Agrisome addresses insects, weeds, fungi and other pests. The only disclosed proof-of-concept (POC) data, however, cover three insect orders: Lepidoptera (moths and caterpillars), Coleoptera (beetles) and Hemiptera (true bugs such as aphids and stink bugs).

Company's own description (paraphrased; no annual report exists)

Trillium Ag has no annual report. Its self-description on trillium.ag, accessed October 2026, is the closest substitute. In paraphrase, the company says it develops new biological platforms for more precise and sustainable crop protection, and that its nature-inspired, AI-designed Agrisome platform has finally delivered on RNAi's potential against insects, weeds, fungi and other pests. It says it is currently helping partner companies build a new class of field-ready biological protectants.

An older directory description, carried over from the company's earlier materials, describes a portfolio of RNAi-based biologicals for crop protection, plant health and yield. That portfolio rested on a patented RNAi trigger called MV-RNA (cited as US Patent 9,200,276) and on nanoparticles for transient or stable trait activation (VisualVisitor profile).

Independent characterisation

Trillium Ag is a pre-commercial, IP-led platform biotech. Its economics depend on licensing and partnering, much like a pharma drug-discovery platform. Its development path is long, regulated and capital-hungry: discovery, then greenhouse trials, then field trials, then regulatory registration (EPA under FIFRA in the US, with equivalent agencies elsewhere), then commercial launch. Each stage can take years.

The company's public positioning moved over 2023–2026:

2023: "Agrisome" was described as a protein-coated RNA biological that Trillium intended to take from R&D to broad-acre use.

2026: Trillium describes itself as a partner-enablement platform. It offers platform licences, co-development programmes, and licence-ready compositions, and it has added AI design tools and a proprietary bioproduction system (nPlanta).

The direction of travel is from "we will make products" towards "we make the toolkit and the IP that major crop-protection companies will license." This is a capital-light strategy that suits a very small team.

Business and revenue model

Revenue model elementDescriptionStatus
Platform licensingA partner receives broad access to the Agrisome platform across products and categoriesOffered (website); no disclosed signed licences
Co-developmentTrillium runs specific programmes with a partner to feed the partner's development pipeline; typically funded R&D plus milestones and royalties (industry norm; Trillium's terms n/d)Offered; trade press (2023) cites "several ongoing collaborations" with unnamed commercial and academic partners
Composition licensingLicence-ready proof-of-concept compositions against Lepidoptera, Coleoptera and Hemiptera targetsOffered
Product sales – nPlantaCell-free protein expression lysate, reaction buffers, vectors and scalable formats, sold through an e-commerce storefront (shopping cart and account login on nplanta.com)Commercial; revenue n/d
Mix (product / service / licensing)——

Value-chain position

Trillium sits at the very start of the crop-protection value chain, in upstream discovery and enabling technology. Downstream are:

  1. Agrochemical and biologicals majors (Bayer, Syngenta, Corteva, BASF, FMC, UPL and others), which handle development, registration, manufacturing and distribution.

  2. Ag retailers and distributors.

  3. Growers.

nPlanta places Trillium in a second value chain as well: life-science research tools, where it sells to R&D labs in medicine, agriculture and biotechnology.

Customer types and end-markets

Customer typeOfferingEnd-market
Global crop-protection companiesPlatform / co-development / composition licencesInsecticides and biopesticides; potentially fungicides and herbicides
Seed and trait companiesCrystal formats described as compatible with seed traitsSeed treatments and traits
Academic research partnersCollaborations (unnamed)Research
Pharma, biotech and ag R&D labsnPlanta cell-free expression kitsProtein expression and research reagents

Strategy

Stated strategic themes (paraphrased from trillium.ag, 2026 and 2023 press releases)

  1. Ending the trade-off between yield and biodiversity. The company's stated vision is that crop protection should eventually defend crops without harming nature.

  2. Realising RNAi in agriculture. Its stated view is that earlier dsRNA approaches failed on stability, specificity and membrane crossing, and that Agrisome's redesigned trigger and delivery system solve those problems.

  3. Partner enablement over vertical integration. Trillium positions itself as a collaborator to global crop-protection companies through three models: platform licensing, co-development and composition licensing.

  4. AI-accelerated design. The 2026 messaging adds "designed with AI" and a proprietary AI toolstack for sequence and particle design.

  5. Scalable bioproduction. nPlanta is presented as the bridge from R&D supply to greenhouse trials, which reduces scale-up friction for partners.

  6. Multi-modal resistance management. Combining RNAi with modes of action from the protein shell is pitched as a way to delay pest resistance.

Strategic initiatives (last 24 months, Oct 2024–Oct 2026)

InitiativeTimingDescriptionSource
nPlanta commercialisation2024–2025Brand set up c. mid-2024; product site and e-commerce refreshed June 2025nplanta.com
Platform expansion: engineered exosomesBy Jan 2026Second delivery layer added for tissue and species specificitytrillium.ag
Platform expansion: field-ready crystalsBy Jan 2026Stabilisation format compatible with seed traitstrillium.ag
AI toolstackBy Jan 2026Proprietary design and optimisation softwaretrillium.ag
Formal partnering menuBy Jan 2026Three-tier licensing and co-development offertrillium.ag
Pest coverage claim widenedBy Jan 2026Messaging extended from insects to weeds, fungi and other peststrillium.ag

Medium-term targets and guidance

None disclosed. No financial targets, cost programmes or ESG commitments with quantified goals have been published.

Products & Services

Agrisome Platform (crop protection)

#ComponentDescription and capabilitiesTarget customerLaunch / versionPricing
1Novel RNAi Trigger (single-stranded; historically branded MV-RNA, "multivalent RNA")A single-stranded, structurally designed RNAi trigger. The company contrasts it with traditional dsRNA, which it says has been problematic in agriculture, and claims higher crop-protection efficacy. Hauser has said the redesigned trigger activates RNAi as strongly as the Nobel-winning dsRNA (AgTech News Substack). The "multivalent" name implies one molecule can target several sequences at once, which matters for resistance managementCrop-protection licenseesCore IP from the 2010s (US 9,200,276 cited)—
2Programmable Nanoparticle (protein shell)Several triggers are assembled into a nanostructure that can be "programmed" to bind a specific set of proteins for each target species or class. The protein shell is said to improve stability, targeting, delivery, uptake and potency, and to add modes of action beyond RNAi. In 2023 trade press this was described as naturally derived, protein-coated RNASameDescribed publicly since 2023—
3Engineered ExosomesThe nanoparticles can be packaged inside exosomes, natural extracellular vesicles that act as a second, biologically native targeting layer. Claimed benefits: tunable tissue and species specificity, protection in harsh environments such as the insect gut, and a modular route to higher potency and more consistent field performanceSameFirst disclosed in the Jan 2026 site update—
4Field-Ready CrystalsNanoparticles, including those inside exosomes, can be locked into natural crystals for long shelf life ("barn-safe" stability). The crystals are described as compatible with seed traits and programmable for just-in-time release of the cargo, and as simplifying production and application. (Analyst note: this resembles how Bt Cry proteins naturally form crystals, a format Fischhoff's Monsanto career was closely tied to.)Same; seed/trait companiesFirst disclosed 2026—
5AI-Driven ToolstackProprietary software that speeds up sequence design and particle composition for each pest and use case, plus tools for bioproduction, formulation and screeningPartners (bundled with licences)First disclosed 2026—
6Composition library (POCs)Licence-ready proof-of-concept compositions against Lepidoptera, Coleoptera and Hemiptera targetsComposition licenseesCurrent—
7"Bio-agricultural pipeline" (unspecified)Further sustainable bio-ag products in R&D, referred to in 2023 press releases———
8Trait-activation nanoparticles (legacy description)Nanoparticles for transient or stable trait activation in plants, aimed at plant health and yield, not only pest controlSeed/trait companiesLegacy description; current status n/d—

Claimed platform attributes (trillium.ag, 2026): more effective; greater specificity with less harm to beneficial organisms; farm-ready stability; a multi-mode advantage for resistance management; adaptive and programmable design that is not rebuilt for each new pest; broad, durable IP protection; and ease of scaling for partners.

nPlanta Cell-Free Protein Expression System

#ProductDescription and specificationsTarget customerLaunchPricing
1nPlanta base lysatePlant-based cell-free lysate for protein expression. Claims eukaryotic-quality folding, disulfide bonds and post-translational modifications (phosphorylation, glycosylation)Pharma, biotech and ag R&D labsBrand set up c. mid-2024; marketed 2025Listed via e-commerce; prices n/d in sources reviewed
2Specialised reaction buffersA library of buffers, each optimised for a particular expression need; used with the lysate plus DNASame2,025—
3Optimised vectors (plasmids)Vectors tuned for faster reactions, complex eukaryotic proteins and post-translational modificationsSame2,025—
4Scalable formatsReaction volumes from 10 µL up to litres, covering prototyping, screening and bioassay validation ahead of industrial biomanufacturingSame2,025—
5WorkflowTwo-part system: combine lysate and buffer, add the vector carrying the gene, incubate 24–48 hours, collect proteinSame2,025—
6Target protein classesGPCRs, cytokines, membrane-bound proteins, glycoproteins, exosomes, virus-like particles (VLPs), enzymes, and multimeric or toxic proteinsSame——
7Custom project supportConsultation for difficult targets through a contact formSame——

nPlanta's stated advantages: protein expression in 24–48 hours (versus weeks in cell culture); no cell culture or sterile facility needed; rapid onboarding; and use alongside existing expression systems.

Financial Narrative

Trillium Agriculture, Inc. is private and has published no financial statements. All values below are not publicly disclosed. The table structure is kept as required, with blank year cells. It should be treated as unreliable.

Income statement

Revenue CAGR FY2021–FY2025: not publicly disclosed.

Commentary

No reported numbers exist, so the analysis below is structural: it describes the likely financial profile implied by the business model, not measured results.

  1. Revenue composition. Revenue most likely comes from three sources: (a) nPlanta reagent sales, probably small and early-stage; (b) sponsored-research or evaluation fees from undisclosed crop-protection collaborators; and (c) possibly government grants. Milestone or royalty income from Agrisome is unlikely before a partner product is registered.

  2. Profitability. Companies at this stage are normally loss-making and funded by equity. Gross margin on reagents can be high, but the scale is too small to cover R&D.

  3. Balance sheet. The company's main asset is its intellectual property, which is unlikely to be capitalised on the balance sheet, and its cash runway. No disclosed debt.

  4. Cash flow. Operating cash burn is driven by R&D salaries, lab costs and patent prosecution. Capex should be modest because the company runs a small lab and outsources field work.

  5. Key financial monitorable. The size and terms of any first platform or composition licence. That deal would be the first external validation of the IP's value.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Business Lines

Business line (analyst-defined)ContentsProducts / servicesCommercial stage

A. Agrisome Crop-Protection Platform

RNAi trigger IP, programmable nanoparticles, engineered exosomes, field-ready crystals, AI toolstack, composition library

Platform licences, co-development, composition licences

Pre-commercial / partnering

B. nPlanta Bioproduction

Plant-based cell-free transcription/translation (TX/TL) system

Lysate, reaction buffers, optimised vectors, scalable reaction formats

Commercial (e-commerce)

Capital Markets

ItemStatus

Share price performance (1 / 3 / 5-year)

Not applicable (private)

Credit ratings (Moody's / S&P / Fitch)

Not rated

Analyst Conclusions

Management guidance

None published. The company's stated near-term focus is moving Agrisome from R&D to broad-scale use through partners (2023 press releases), and scaling partner adoption through nPlanta and its AI tools (trillium.ag, 2026).

Consensus expectations

None (no analyst coverage).

Bull case

  1. Technical differentiation in the category's hardest problem. If the protein-shell, exosome and crystal stack really does work against insect orders that resist orally ingested dsRNA (about 85% of pests, by Hauser's figure), Trillium holds a key that dsRNA producers lack.

  2. Network-driven route to licensing. With Gutterson (former Corteva CTO) on the board and Fischhoff (Monsanto's Bt pioneer) chairing the SAB, Trillium has direct access to the decision-makers who sign platform deals.

  3. Capital-light optionality. Three licensing models, POCs in three insect orders, and a reagent business generating cash give multiple ways to win without building a sales force.

Bear case

  1. Ten years without a named partner. The company was founded in 2016 and still discloses no named licensee, field data or regulatory filing. That points to slow validation.

  2. A competitor has already set the benchmark. GreenLight's registered dsRNA product and its large-scale production weaken Trillium's argument that dsRNA cannot work, at least for beetles.

  3. Execution and financing fragility. A team possibly as small as 3, undisclosed finances, and complex multi-layer constructs create risk on runway, cost of goods and regulatory approval.

Key catalysts and monitorables (next 12 months)

Catalyst / MonitorableWhy it matters
Announcement of a named platform or composition licenceFirst external validation of the value of the IP
Disclosure of greenhouse or field-trial dataEvidence that the technology works under real conditions
Any EPA Experimental Use Permit or registration filingStart of the regulatory path
Funding round disclosure (or SEC Form D)Runway and investor validation
nPlanta customer wins or distribution partnershipsStrength of the non-dilutive revenue line
Leadership hires (CBO, CSO, regulatory head)Signal of a move to commercial scale
Competitor moves (GreenLight expansion, majors' internal RNAi)Pressure on the competitive window
New patent grants (exosome, crystal formats)Durability of the IP

Analyst verdict

Trillium Agriculture, Inc. is not the listed company the input record assumed. It is a small, private, IP-intensive ag-biotech platform with an ambitious scientific thesis and an elite advisory bench, but very little public evidence of commercial traction. Any institutional reader should start from that fact. No financial statements, valuation or ownership data exist in the public domain, and none have been estimated here.

The scientific logic is coherent and well targeted. Agricultural RNAi has historically been held back by three things: dsRNA instability, poor uptake in most insect orders, and challenges with field persistence. Trillium has built a modular answer to each. Its single-stranded trigger addresses potency and specificity. The protein-shell nanoparticles and engineered exosomes address delivery and gut survival. The natural crystals address storage and controlled release. An AI design layer and the nPlanta bioproduction system speed up iteration and scale-up for partners. In 2026 the company recast itself as a licensor and co-developer rather than a product company, which is the right strategic choice for an organisation of its apparent size.

What is missing is proof outside the lab. About ten years after its founding, Trillium has named no licensee, published no field data and disclosed no regulatory filing. Meanwhile, at least one competitor has registered a sprayable RNA product in the US, which has moved the category from theory to reality. Trillium's opportunity window is real but finite. Its differentiation matters most for the insect orders and pest classes where dsRNA does not work.

Verdict: High-risk, high-optionality early-stage platform. Monitor rather than engage at scale. The decisive near-term signal is a named partnership with a global crop-protection company backed by greenhouse or field data. Until that happens, Trillium Ag should be treated as a credible but unproven technology option, and its strongest verifiable assets are its patent claims and the calibre of its board and scientific advisors.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior roles / backgroundCompensation

Todd Hauser

Co-Founder & Chief Executive Officer

2016–present

Described as a seasoned biotech and gene-silencing entrepreneur (AgTech News Substack); prior company affiliations not detailed in sources reviewed

n/d (private)

Paul Olivier

Co-Founder (current title n/d; likely scientific lead)

2016–present

Seattle-area scientist; a Seattle-area inventor (Jean) Paul Olivier holds multiple plant-biotech patents, several assigned to Targeted Growth, Inc.; link to the co-founder is plausible but unconfirmed

—

David Hensel

Listed as "founder" by MarketScreener

—

Former Head of Media Relations and Director of Brand & Marketing at Grand Banks Yachts Ltd.

—

Board of Directors

NameRoleJoinedBackgroundEducationIndependence

Todd Hauser

Director (presumed, as CEO and co-founder)

2016

See above

—

Non-independent (executive)

Neal Gutterson, PhD

Director

2023

Partner & CTO, Radicle Growth (early-stage food and ag tech fund). Retired as CTO of Corteva Agriscience in 2020. Joined DuPont (later Corteva) in 2014. Earlier, President & CEO of Mendel Biotechnology. Board seats at CGIAR System Board (from autumn 2020), CIMMYT and the Biotechnology Innovation Organization. Chairman at Boost Biomes. Former board member at GrassRoots Biotechnology and DNA Plant Technology

BA, Yale University; PhD, UC Berkeley

Likely independent. Radicle Growth affiliation could indicate investor representation; unconfirmed

Board of Directors — David Fischhoff, PhD

NameRoleAppointedBackground

David Fischhoff, PhD

Chair, Scientific Advisory Board

14 June 2023

33 years at Monsanto. Roles included Chief Scientist of The Climate Corporation and Co-President of Cereon Genomics (a Monsanto–Millennium Pharmaceuticals research venture). Widely credited with leading the discovery and development of insect-resistant (Bt) crops. Nearly four decades in ag R&D (iGrow News)

Directors' Remuneration

ItemStatus

Board size

n/d (at least 2 inferred)

Committees (audit, compensation, nominating)

n/d. Unlikely to be formal at this stage

Recent executive changes

None reported apart from the board and SAB additions in 2023

Institutional ownership (top 10)

Not applicable (private). Investors not publicly disclosed

Insider ownership

n/d. Founders presumed to be significant holders

Competitive Landscape

Key Competitors

#CompetitorOwnershipRelevancePositioning vs. Trillium
1

GreenLight Biosciences

Private (taken private 2023)

Cell-free dsRNA production; ledprona (Calantha) EPA-registered Dec 2023 for Colorado potato beetle (analyst recall)

Ahead commercially with a registered product. Uses dsRNA, the approach Trillium argues against. Large-scale production cost advantage

2

Bayer Crop Science

Listed (Bayer AG)

RNAi traits (e.g., corn rootworm RNAi in SmartStax PRO); biologicals

Incumbent with trait-based RNAi; potential licensee and competitor

3

Syngenta Group (Biologicals)

Chinese state-owned (ChemChina/Sinochem)

Large biologicals portfolio; RNAi research

Potential licensee and competitor

4

Corteva Agriscience

Listed (NYSE: CTVA)

Biologicals (via Stoller and Symborg acquisitions); RNAi research history

Gutterson link; potential licensee

5

BASF Agricultural Solutions

Listed (BASF SE)

Biologicals and traits

Potential licensee

6

FMC Corporation

Listed (NYSE: FMC)

Biologicals; pheromones

Potential licensee

7

RNAissance Ag

Private

RNAi biopesticides

Direct peer (start-up)

8

AgroSpheres

Private

Bioparticle encapsulation and delivery of actives, including RNA

Direct peer on delivery

9

Pebble Labs

Private

Microbe-delivered RNA for crop and animal health

Direct peer

10

Vestaron

Private

Peptide-based bioinsecticides

Adjacent: precision biologicals for insects

11

Provivi

Private

Pheromone-based pest control

Adjacent

12

Micropep Technologies

Private

Micropeptide crop protection

Adjacent

Peer Comparison FY2024

MetricTrillium AgCorteva (total)Bayer Crop ScienceFMC

Revenue FY2024

—

≈ USD 16.9 B

≈ EUR 22.3 B

≈ USD 4.25 B

Revenue growth FY2024

—

≈ -3% to -4%

≈ -4%

≈ -5%

Margins

n/d (likely loss-making)

Positive operating EBITDA

Positive (segment EBITDA before special items)

Positive

R&D intensity

n/d (likely >100% of revenue)

≈ 8%

≈ 10%

≈ 6%

Commercial RNAi product

None (pre-commercial)

No sprayable RNAi product

Trait-based RNAi

—

Recent Developments

Trillium Ag issues very few press releases. Only the following developments in the 18-month window could be verified or reasonably dated. Earlier 2023 items are listed separately for context and are not counted as part of the window.

*Context: pre-window developments

Items with no reported events: * guidance revisions, litigation, regulatory actions, restructurings, layoffs and hiring announcements.

Company Snapshot

3

Employees

2016

Founded

Washington, US

Headquarters

SWOT Analysis

Strengths

  • Differentiated trigger chemistry. The company says its single-stranded RNAi trigger activates RNAi as strongly as dsRNA while avoiding dsRNA's known problems in agriculture (AgTech News Substack; trillium.ag).
  • Layered delivery stack. Protein-shell nanoparticles, engineered exosomes and field-ready crystals (trillium.ag, 2026) address degradation and gut uptake directly.
  • Patent estate. Issued patents across key global regions (trillium.ag, 2026), with MV-RNA linked to US 9,200,276 (VisualVisitor).
  • Elite governance network. Board member Neal Gutterson is a former Corteva CTO, and SAB Chair David Fischhoff led Monsanto's insect-resistant crop work (iGrow News, 2023).
  • Second revenue line. The nPlanta reagent business has been commercially live through e-commerce since 2025 (nplanta.com).
  • Breadth of POCs. Licence-ready compositions in three major insect orders (trillium.ag).

Weaknesses

  • No named commercial partners after about ten years of operation (trillium.ag; press releases).
  • No disclosed field-trial or regulatory milestones in any source reviewed.
  • Very small organisation. One directory reports 3 employees (VisualVisitor).
  • Opaque finances. No disclosed funding rounds or revenue, so runway risk cannot be assessed.
  • Inconsistent public records. HQ is listed in both Bellingham and Seattle, and the founder lists conflict (VisualVisitor vs. MarketScreener).
  • Sparse newsflow. The last major press release found was from June 2023.

Opportunities

  • Category validation. The EPA's December 2023 registration of a sprayable dsRNA product (GreenLight ledprona) demonstrates a regulatory path.
  • Majors need new modes of action. Resistance and active-ingredient withdrawals push majors to license external innovation.
  • Seed-trait route. Crystals are described as compatible with seed traits, which could open trait licensing (trillium.ag).
  • Expansion beyond insects into weeds and fungi, as the company now claims (trillium.ag, 2026).
  • nPlanta adjacencies. The product targets GPCRs, glycoproteins and VLPs, which are pharma-relevant markets (nplanta.com).
  • AI-driven design. AI tools can shorten discovery cycles and make Trillium more attractive as a partner (trillium.ag).

Threats

  • GreenLight's head start. It has an approved product and large-scale production.
  • Incumbents' internal RNAi programmes at Bayer and others.
  • Regulatory scrutiny of new nanoparticle and exosome formulations.
  • Funding environment. Ag-tech venture funding contracted sharply in 2023–2024 (industry-wide).
  • Cost-of-goods pressure from multi-component constructs.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
June 2025nPlanta website refreshed with full product line (2-part system, buffers, vectors, scalable formats) nplanta.com (asset dates)Shows commercial intent for the reagent business
2025nPlanta e-commerce storefront operating (cart, account login) nplanta.comFirst visible direct-sales channel
2025Legal entity "Trillium Agriculture, Inc." confirmed as nPlanta owner nplanta.comEntity resolution
Jan 2026Corporate website relaunched with "inspired by nature, designed with AI" positioning trillium.agStrategic repositioning towards AI and platform enablement
Jan 2026Engineered exosome and field-ready crystal modules disclosed trillium.agPlatform broadened
Jan 2026Three partnering models formalised (platform, co-development, composition licensing) trillium.agClear go-to-market model
Jan 2026Licence-ready POCs disclosed across Lepidoptera, Coleoptera and Hemiptera trillium.agIndicates portfolio maturity
2026Company claims a "growing list" of global crop-protection collaborators trillium.agCommercial traction claim (unquantified)
Early 2023Neal Gutterson joins the Board iGrow News; AgriBusiness Global–
14 June 2023David Fischhoff named SAB Chair iGrow News–
2023CEO podcast and media round (Ag Tech Talk, AgTech News, iGrow News, North American Ag Spotlight) Various–

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.